Skip to main content
OpenTrials
Completed

NCT Number: NCT05080868

Infantile Hemangioma With Minimal or Arrested Growth : Epidemiology, Clinical Characteristics and Evolution

Infantile hemangioma (IH) is the most common vascular tumor of infancy, characterized by its clinical history. Absent at birth or present under the form of a premonitory mark, they display a rapid proliferative phase starting in the first weeks of life. Then, after a plateau phase, they slowly involute. However, a subtype of IH named "abortive", "minimal or arrested growth", "reticular" or "telangiectatic" hemangioma differs from typical IH because it doesn't have a proliferative component, or only a minimal one. This subtype of hemangioma has been recently described and data are lacking regarding its proportion among infantile hemangioma and its differences with "classic" infantile hemangioma. The aim of this study is to estimate the proportion of abortive hemangioma among infantile hemangioma. Also, the investigators aim to compare the clinical characteristics of "classic" infantile hemangiomas and abortive hemangiomas. Lastly, investigators wished to study the evolution of abortive hemangioma.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Hemangioma, Capillary Hemangioma Neoplasms Neoplasms by Histologic Type Neoplasms, Vascular Tissue

Age range

1 day–18 year

Sex eligibility

All sexes

Study type

Observational

Primary location

CHRU de Nancy

Nancy, Grand Est, 54000, France

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Children between 0 and 18 years old
  • Followed in the dermatology department of CHRU de Nancy between January 2014 and December 2020
  • Presenting with one or more infantile hemangioma

Exclusion criteria

  • Those whoes guardian does not want his data to be collected in this study

Treatment and study plan

Primary outcomes

  1. Proportion of abortive hemangioma among infantile hemangioma

    Time frame: baseline

    Proportion of abortive hemangioma among infantile hemangioma

Secondary outcomes

  1. To compare the epidemiological characteristics between infantile hemangioma and abortive hemangioma : sex

    Time frame: baseline

    Compare sex predominance between infantile hemangioma and abortive hemangioma

  2. To compare the epidemiological characteristics between infantile hemangiomas and abortive hemangiomas : prematurity

    Time frame: baseline

    Compare prematurity rates between infantile hemangiomas and abortive hemangiomas

  3. To compare the epidemiological characteristics between infantile hemangiomas and abortive hemangiomas : birthweight

    Time frame: baseline

    Compare birthweight between infantile hemangiomas and abortive hemangiomas

  4. To compare the clinical characteristics between infantile hemangiomas and abortive hemangiomas : localization

    Time frame: baseline

    Compare localization between infantile hemangiomas and abortive hemangiomas

  5. To compare the clinical characteristics between infantile hemangiomas and abortive hemangiomas : treatment

    Time frame: baseline

    le hemangiomas and abortive hemangiomaCompare treatment between infanti

  6. To compare the clinical characteristics between infantile hemangiomas and abortive hemangiomas : complications

    Time frame: baseline

    Compare complications between infantile hemangiomas and abortive hemangioma

  7. To compare the clinical characteristics between infantile hemangiomas and abortive hemangiomas : size

    Time frame: baseline

    Compare size (focal, extended or segmental) between infantile hemangiomas and abortive hemangioma

  8. To study the evolution of abortive hemangioma : erythematous macule

    Time frame: through study completion, an average of 4 years

    Evaluation of the fading of erythematous macule between the stage of maximal proliferation and the last follow-up

  9. To study the evolution of abortive hemangioma : papules of proliferation

    Time frame: through study completion, an average of 4 years

    Evaluation of the regression of the papules of proliferation between the stage of maximal proliferation and the last follow-up

  10. To study the evolution of abortive hemangioma : telangiectasias

    Time frame: through study completion, an average of 4 years

    Evaluation of the fading of telangiectasias between the stage of maximal proliferation and the last follow-up

  11. To study the evolution of abortive hemangioma : halo of vasoconstriction

    Time frame: through study completion, an average of 4 years

    Evaluation of the fading of the vasoconstricted halo between the stage of maximal proliferation and the last follow-up

  12. To study the evolution of abortive hemangioma : areas of vasoconstriction

    Time frame: through study completion, an average of 4 years

    Evaluation of the fading of vasoconstricted areas between the stage of maximal proliferation and the last follow-up

  13. To study the evolution of abortive hemangioma : dilated veins

    Time frame: through study completion, an average of 4 years

    Evaluation of the fading of dilated veins between the stage of maximal proliferation and the last follow-up

Sponsors and collaborators

Lead sponsor

Central Hospital, Nancy, France

Other

Registry information

Official study title

Comparing Epidemiological and Clinical Characteristics of Infantile Hemangioma With Minimal or Arrested Growth (IH-MAG) and Classic Infantile Hemangioma : a Retrospective Study

Important dates

Study start
2021
Primary completion
2021
Study completion
2021
First posted
Oct 18, 2021
Registry last updated
Oct 18, 2021

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.